Hospital‐Admitted Injection‐Related Infections Among Incarcerated People Who Inject Drugs in Australia: A Retrospective Cohort Study
Open Access
- 14 June 2026
- journal article
- research article
- Published by Wiley in Medical Journal of Australia
- Vol. 224 (6) , e70224
Abstract
Objectives: To characterise the clinical, microbiological and economic burden of hospital‐admitted, injection‐related infections among incarcerated people who inject drugs. Study Type: Retrospective observational cohort study. Setting: Secure unit of the Princess Alexandra Hospital, Brisbane, Australia. Participants: Adults incarcerated in Queensland prisons who were admitted to hospital with an injection‐related infection between 1 July 2019 and 30 June 2023. Main Outcome Measures: Types of injection‐related infection, microbiological findings, requirement for surgical or radiological source control, hospital length of stay and inpatient healthcare costs. Results: There were 321 hospital admissions for injection‐related infection among 265 patients, accounting for 282 unique infections. Most patients were male (241; 90.9%), with a mean age of 33 years (standard deviation [SD], 7.4 years), and 76 (28.7%) identified as First Nations. The most frequent infections were soft tissue infections (77/282; 27.3%), acute hepatitis C (64/282; 22.7%) and cellulitis (43/282; 15.2%). Surgical or radiological source control was required in 95 infections (34.0%), and infectious diseases consultation occurred in 130 infections (46.1%). Among 39 true‐positive blood cultures, Staphylococcus aureus was identified in 17 (43.6%), Burkholderia species in 10 (25.6%) and non‐tuberculous Mycobacterium species in 3 (7.7%). Among the 218 non‐acute hepatitis C infections, 50 (22.9%) were hepatitis C virus (HCV) RNA positive. Overall, HCV RNA was present in 114 of 282 infections (40.4%). The total inflation‐adjusted inpatient cost was $8.39 million, with a median cost per infection of $11,602 (interquartile range, $7426–$34,544). Conclusion: Injection‐related infections among incarcerated people who inject drugs were associated with substantial morbidity and healthcare costs in this large hospital cohort. A wide clinical spectrum was observed, including atypical pathogens, and clinically overt acute hepatitis C requiring hospital admission. These findings describe a significant burden of preventable disease in custodial settings and support the introduction of established primary prevention and harm‐reduction interventions in prisons.Keywords
This publication has 38 references indexed in Scilit:
- Notification of Nontuberculous Mycobacteria: An Australian PerspectiveAnnals of the American Thoracic Society, 2017
- Injection Drug Use and Outcomes After Surgical Intervention for Infective EndocarditisThe Annals of Thoracic Surgery, 2015
- Estimating the cost-effectiveness of needle-syringe programs in AustraliaAIDS, 2012
- The Molecular Epidemiology of the Highly Virulent ST93 Australian Community Staphylococcus aureus StrainPLOS ONE, 2012
- A rare case of community acquired Burkholderia cepacia infection presenting as pyopneumothorax in an immunocompetent individualAsian Pacific Journal of Tropical Biomedicine, 2012
- [Evaluation of needle exchange program at Pereiro de Aguiar prison (Ourense, Spain): ten years of experience].2012
- Drug Users Seeking Emergency Care for Soft Tissue Infection at High Risk for Subsequent Hospitalization and DeathJournal of Studies on Alcohol and Drugs, 2008
- Methicillin-susceptible, non-multiresistant methicillin-resistant and multiresistant methicillin-resistant Staphylococcus aureus infections: a clinical, epidemiological and microbiological comparative studyEuropean Journal of Clinical Microbiology & Infectious Diseases, 2008
- Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studiesBMJ, 2007
- Prison‐based syringe exchange programmes: a review of international research and developmentAddiction, 2003